(WASHINGTON) — Federal health regulators have delayed a decision on whether to approve the first pill shown to prevent HIV infection, the drug’s manufacturer says. Gilead Sciences disclosed Friday that the Food and Drug Administration will take three more months to review its application for Truvada, after the company submitted additional materials to the agency [...]
read more
Last week, a group of 55 U.S. physicians sent a letter to the U.S. Food & Drug Administration (FDA), urging the agency not to approve the use of Gilead's HIV/AIDS treatment drug Truvada for use as an HIV prevention pill - also known... Read Post
The Food and Drug Administration is delaying by three months a decision on whether to approve a drug for preventing infection with HIV, the virus that causes AIDS. An agency decision on the drug Truvada, made by Gilead Sciences, was... Read Post
The Food and Drug Administration (FDA) on Monday approved the first drug shown to reduce the risk of HIV infection, a milestone in the 30-year battle against the virus that causes AIDS. The agency approved Gilead Sciences’ pill Truv... Read Post